Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.

Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants. Vaccine. 2020 Sep 10;: Authors: van Rijn PA, Maris-Veldhuis MA, Grobler M, Wright IM, Erasmus BJ, Maartens LH, Potgieter CA Abstract African horse sickness virus (AHSV) is a virus species in the genus Orbivirus of the family Reoviridae causing African Horse Sickness (AHS) in equids with a mortality of about 95% in naïve horses. AHS causes serious losses in developing countries where horses play a central role in draft power and transportation. There are nine AHSV serotypes inducing no or low cross-neutralizing antibodies. AHSV is spread by biting Culicoides midges. AHS is endemic in sub-Saharan Africa, and a serious threat outside Africa, since Culicoides species in moderate climate conditions are spreading the closely related bluetongue virus. AHS outbreaks will be devastating for the equestrian industry in developed countries. Live-attenuated vaccines (LAVs) are licensed, marketed and in use in Africa. Their application is controversial with regard to safety issues. LAVs are not allowed in AHS-free countries. We here studied inactivated AHSV with different adjuvants in guinea pigs and horses. Subcutaneous and intramuscular vaccination were studied in horses. Local reactions were observed after prime and boost vaccination. In general, neutralizing antibodies (nAbs) titres were very low after prime vaccination, whereas boost ...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research